AAM
CVAC

Alpine Associates Management’s CureVac CVAC Stock Holding History

Alpine Associates Management’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,295,422
Closed -$12.4M – 74
2025
Q3 		$12.4M Buy
2,295,422
+324,247
+16% +$1.75M 0.75% 27
2025
Q2 		$10.7M Buy
+1,971,175
New +$7.82M 0.57% 42

Other funds holding CVAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Alpine Associates Management's CVAC Position: Q4 2025 in Review

Alpine Associates Management sold out of CureVac (CVAC) in Q4 2025, closing a stake of 2,295,422 shares — an estimated $12.4M sold.

Alpine Associates Management first reported a position in CVAC in Q2 2025 and held it in 2 quarters. The position peaked at $12.4M in Q3 2025. 57 funds tracked by Wall St. Rank hold CVAC as of Q4 2025.

  • Alpine Associates Management reported no remaining CureVac position as of Q4 2025 after selling out during the quarter.
  • Alpine Associates Management sold 2,295,422 CureVac shares in Q4 2025, an estimated $12.4M.
  • Alpine Associates Management first reported a position in CureVac in Q2 2025 and held it in 2 quarters.
  • Alpine Associates Management's CureVac position peaked at $12.4M in Q3 2025.
  • 57 funds tracked by Wall St. Rank held CureVac as of Q4 2025.

Based on Alpine Associates Management's 13F filing for Q4 2025, filed 5 Feb 2026.